SS-31 vs MOTS-c: Evidence, Mechanisms and Safety for Mitochondrial Research
SS-31 and MOTS-c are both studied in mitochondrial biology but through distinct mechanisms, different evidence bases, and at very different stages of clinical development. Which one fits your research depends almost entirely on the biological question you are asking.
Research summary
SS-31 (elamipretide) is a synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in mitochondrial DNA that functions as a metabolic signaling molecule.[1][2]
- Elamipretide (Forzinity) received US FDA accelerated approval on 19 September 2025 to improve muscle strength in adults and paediatric patients with Barth syndrome weighing at least 30 kg; MOTS-c remains investigational.[3]
- No published head-to-head SS-31 vs MOTS-c human trial was identified in the sources reviewed. The comparison here is indirect.
Remy Research materials are for in-vitro laboratory research only, not human or veterinary use.
Summary written November 14, 2026, at first publication.
Update History ▾
Research-use-only framing applied throughout in line with Remy editorial standards.
SS-31 (elamipretide) is a synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. Preclinical studies link this interaction to preservation of cristae architecture and electron transport. It is a structural intervention at the membrane level. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in mitochondrial DNA that functions as a metabolic signaling molecule, with AMPK-dependent effects and changes in nuclear gene expression under metabolic stress. One acts on mitochondrial structure; the other acts through mitochondrial signaling to reshape cellular metabolism.
The short answer: Choose SS-31 when your research centres on mitochondrial membrane integrity, oxidative phosphorylation coupling, cardiolipin biology, or ischemia–reperfusion injury models. Choose MOTS-c when your work focuses on insulin sensitivity, glucose metabolism, obesity, aging-related metabolic decline, or exercise-mimetic biology. SS-31 carries a substantially larger human evidence base. Elamipretide (Forzinity) received US FDA accelerated approval on 19 September 2025 to improve muscle strength in adults and paediatric patients with Barth syndrome weighing at least 30 kg.[3] Continued approval may depend on verification of clinical benefit in a confirmatory trial. MOTS-c remains investigational; a trial registration does not establish efficacy or safety. Neither pharmaceutical approval nor clinical safety data extend to research-grade peptides: Remy Research supplies SS-31 and MOTS-c as research-grade reagents for in-vitro use only, with no dosing, administration, or therapeutic guidance provided.
What Is SS-31 (Elamipretide) in the Context of Research?
SS-31 is a synthetic tetrapeptide (D-Arg-2ʹ,6ʹ-dimethylTyr-Lys-Phe-NH₂) engineered with alternating aromatic and cationic residues to accumulate selectively in mitochondria. SS-31 interacts with cardiolipin in the inner mitochondrial membrane, a phospholipid essential to cristae folding and ETC organisation.
Key mechanistic features relevant to laboratory researchers:
- Cardiolipin binding and cristae stabilisation. SS-31 interacts with cardiolipin and has preserved mitochondrial membrane architecture in preclinical models. A mechanistic study linked cardiolipin binding to reduced cytochrome c peroxidase activity, preserved electron-carrier function and improved ATP synthesis in isolated mitochondria.[1]
- Bioenergetic effects. SS-31 has improved ATP synthesis and oxidative phosphorylation coupling in preclinical experiments. In aged mouse skeletal muscle, treatment improved ATP production and the P/O ratio, a measure of ATP produced relative to oxygen consumed.[4]
- Redox modulation. In the same aged-mouse study, SS-31 reduced markers of oxidative damage and increased the reduced-to-oxidised glutathione ratio in skeletal muscle.[4] These findings concern a specific animal model, not demonstrated anti-aging benefits in humans.
- Preclinical scope. SS-31 has been investigated in models of ischemia–reperfusion injury and skeletal muscle aging.[5][4] Such models help test mitochondrial mechanisms; they do not establish efficacy across human diseases.
- Regulatory note. The medicinal product elamipretide (Forzinity) holds a specific US indication for Barth syndrome.[3] Research-grade SS-31 vials are not licensed medicines and are not interchangeable with the approved pharmaceutical formulation.
For a full review of SS-31 mechanisms, preclinical evidence and safety signals, see SS-31 Peptide Benefits, Side Effects and FDA Approval.
What Is MOTS-c for Mitochondrial and Metabolic Research?
MOTS-c is a mitochondrial-derived peptide consisting of 16 amino acids, encoded within a short open reading frame in the 12S rRNA region of mitochondrial DNA.[2] In cell experiments, MOTS-c translocates to the nucleus under metabolic stress, where it modulates nuclear gene expression involved in metabolic regulation and stress adaptation – a form of retrograde mitochondrial signaling that has attracted particular interest in aging and metabolism research.[6]
Core mechanistic properties for researchers:
- Metabolic regulation. MOTS-c is studied for glucose metabolism and energy homeostasis. In the original discovery study, its cellular actions affected the folate cycle and de novo purine biosynthesis, leading to AMPK activation. Treatment improved insulin sensitivity and reduced diet-induced obesity in mice.[2] MOTS-c primarily influences metabolic signaling and adaptation rather than direct membrane biophysics.
- Exercise-related biology. MOTS-c is often studied for its exercise-mimicking properties. In one human exercise study, circulating MOTS-c showed a trend towards an increase after endurance exercise; the statistically significant increase was in humanin, a different mitochondrial-derived peptide.[7] Measuring endogenous MOTS-c after exercise does not establish the effects of administering it.
- Preclinical disease links. MOTS-c is investigated for its role in obesity and insulin resistance. Rodent experiments provide evidence of metabolic effects, but these findings cannot be assumed to translate into clinical benefits.
- Evidence stage. MOTS-c lacks established clinical efficacy and a well-characterised human safety profile. No MOTS-c treatment trial had results posted on ClinicalTrials.gov when checked on 14 November 2026. A separate completed study of CB4211 concerns an analogue, not the same compound.[8]
For a detailed look at MOTS-c mechanisms, aging data and safety gaps, see MOTS-c Benefits and Side Effects: What Studies Show.
SS-31 vs MOTS-c: How They Compare at a Glance
The table below is a quick reference for labs deciding which peptide aligns with a given research question. Both peptides represent distinct areas of mitochondrial research. The research-fit judgments below are based on their mechanisms and published models, not a direct comparative trial.
| Factor | SS-31 (Elamipretide) | MOTS-c |
|---|---|---|
| Compound identity | Synthetic tetrapeptide (4 aa), D-Arg-dimethylTyr-Lys-Phe-NH₂ | Mitochondrial-derived peptide (16 aa), encoded in the mtDNA 12S rRNA region |
| Primary target / mechanism | Cardiolipin in the inner mitochondrial membrane; effects on membrane architecture and electron transport | AMPK-dependent metabolic signaling and stress-responsive nuclear gene expression |
| Best-suited research focus | Mitochondrial membrane bioenergetics, cardiolipin biology, ATP coupling, ischemia–reperfusion injury | Insulin resistance, obesity, exercise signaling, metabolic adaptation |
| Clinical development | Forzinity has a specific US accelerated approval; the Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet its primary endpoints | No MOTS-c treatment trial with posted results at review; the CB4211 analogue completed a Phase 1a/1b study |
| Human evidence base | Randomised trials include SPIBA-201 (12 patients) and MMPOWER-3 (218 patients); results differ by indication | Endogenous-level studies; no interventional trial with posted results at review; CB4211 analogue evidence must be assessed separately |
| Safety profile | Injection-site reactions are common; serious hypersensitivity is a labelled risk | Human safety remains insufficiently characterised |
| Regulatory status | Forzinity: US accelerated approval to improve muscle strength in Barth syndrome adult and paediatric patients weighing at least 30 kg; this does not establish UAE/GCC authorisation | Investigational; trial registration is not marketing approval |
| Example experimental models | Aged mouse skeletal muscle; renal ischemia–reperfusion | Diet-induced obesity and insulin resistance in mice; stressed cell cultures; neuropathic pain models |
Both peptides are studied in mitochondrial biology but through different mechanisms: SS-31 acts at the mitochondrial membrane, while MOTS-c is involved in metabolic signaling and cellular adaptation.
Decisive Factor 1: Mechanism and Site of Action
Mechanistic fit is usually the main driver when choosing between these peptides for laboratory research. The published literature includes cell and animal experiments; Remy Research reagents are supplied for in-vitro use only. The two compounds operate at fundamentally different biological levels, and matching your tool to your question matters more than any other consideration.
SS-31:
- SS-31 targets the inner mitochondrial membrane by binding cardiolipin – a lipid essential to cristae geometry and ETC supercomplex organisation. This binding stabilises mitochondrial structure, supports electron transport, and preserves cytochrome c’s role as an electron carrier rather than a peroxidase.[1]
- SS-31 has improved mitochondrial function and ATP production in preclinical models. In aged mouse skeletal muscle, treatment improved redox balance and oxidative phosphorylation coupling; the results do not demonstrate a general benefit in humans.[4]
- SS-31’s membrane effects in preclinical models make it relevant for research on mitochondrial membrane damage, cardiolipin peroxidation, and respiratory chain deficiency.
MOTS-c:
- MOTS-c acts as a stress-responsive peptide that translocates to the nucleus under metabolic stress. Cell experiments show AMPK-dependent nuclear translocation and interactions with stress-responsive transcription factors including NRF2.[6] This positions it as a retrograde mitochondrial signal — a messenger from organelles to nucleus.
- MOTS-c activates AMPK and influences glucose handling and metabolic pathways in experimental models rather than directly modifying mitochondrial membrane biophysics. A 2026 study in Free Radical Biology & Medicine found improved intrinsic skeletal-muscle mitochondrial bioenergetics in mice through AMPK- and PGC-1α-dependent pathways, without an apparent increase in respiratory protein content.[9] This supports improved mitochondrial performance, not a demonstrated increase in mitochondrial biogenesis.
Implications for experimental design:
- SS-31 is better aligned for experiments centred on mitochondrial membrane integrity, cardiolipin biology (e.g. Barth syndrome models), respiratory chain efficiency, redox modifications of mitochondrial proteins, and recovery from acute injury.
- MOTS-c is better aligned for experiments probing metabolic syndrome, exercise mimetics, aging-associated decline in metabolic resilience, and cross-talk between mitochondria and nucleus.
Winner: Mechanistic specificity depends on the question. SS-31 wins for direct mitochondrial membrane and cardiolipin-focused studies. MOTS-c wins for systemic metabolic signaling questions. This makes the winner conditional rather than universal – a reflection of the distinct mechanisms these peptides employ.
Decisive Factor 2: Human vs Animal/In-Vitro Evidence
Lab buyers planning translational work often want to know where robust human data exist – even if their own experiments are preclinical. The gap here is substantial.
SS-31 (elamipretide) evidence trajectory:
Human clinical data include multiple randomised trials. In Barth syndrome, SPIBA-201 began with a 12-patient randomised crossover period. Neither the 6-minute walk distance nor fatigue co-primary endpoint showed superiority at 12 weeks. Ten patients entered the open-label extension, which continued for up to 192 weeks. Improvements in knee-extensor strength during open-label follow-up supported accelerated approval; this uncontrolled result does not carry the same evidential weight as a positive placebo-controlled outcome.[10] A confirmatory trial is required to verify clinical benefit.[3]
In primary mitochondrial myopathy, MMPOWER-3 randomised 218 patients and found no significant improvement over placebo in either 6-minute walk distance or fatigue at 24 weeks.[11] The Barth syndrome approval should not be generalised to other mitochondrial disorders.
Preclinical work includes improvements in exercise tolerance, skeletal-muscle bioenergetics and redox balance in aged mice, and protection in renal ischemia–reperfusion models.[4][5] These findings support mechanistic research, not claims of proven human anti-aging or exercise benefits.
MOTS-c evidence:
Much of the MOTS-c evidence comes from rodent models of diet-induced obesity, insulin resistance and aging. In cell culture, a study of aged human placenta-derived mesenchymal stem cells reported improved mitochondrial homeostasis with reduced reactive oxygen species and altered lipid metabolism.[12] These results are specific to the experimental cells and conditions.
Published human physiological studies measure endogenous MOTS-c. In lipid-infusion experiments, circulating levels rose to approximately 232% of baseline in controls and 349% in women with polycystic ovary syndrome — about 2.3 and 3.5 times baseline, respectively.[13] The exercise study cited above reported a trend for MOTS-c, not a statistically significant increase. Neither study tested MOTS-c as a treatment.
Interventional research on native MOTS-c has not yet reported results. A ClinicalTrials.gov search on 14 November 2026 found no MOTS-c treatment trial with posted results, and a registry entry by itself does not establish efficacy or safety. Separately, NCT03998514 is a completed Phase 1a/1b study of CB4211 in 88 participants.[8] The developer identifies CB4211 as a MOTS-c analogue; findings for that compound cannot be treated as results for native MOTS-c.[14]
No published head-to-head SS-31 vs MOTS-c human trial was identified in the sources reviewed. The comparison here is indirect.
Winner: SS-31. SS-31 has more extensive human trial data and a defined approved indication, making it the stronger reference where translation to human pathophysiology is a priority. MOTS-c remains at an earlier stage, with most supporting findings still preclinical and no interventional trial results available.
Decisive Factor 3: Safety Signals and Research Limitations
Safety data for these peptides come from formal elamipretide clinical trials and early MOTS-c preclinical studies – not from uncontrolled use of research-grade reagents.
SS-31 / elamipretide safety:
Published trial data and the FDA prescribing information for Forzinity report:[15]
- Common adverse events: Injection-site reactions, including redness, pain, induration, itching, bruising and urticaria, are the most frequent adverse reactions in the Forzinity label.
- Serious hypersensitivity: The label warns about serious allergic reactions requiring emergency medical intervention. A history of serious hypersensitivity to elamipretide or the product’s excipients is a contraindication. Small trials and open-label follow-up cannot exclude uncommon or delayed harms.
- Limitations: Most safety data come from defined dosing regimens and pharmaceutical-grade formulations not identical to lab-grade solutions. The Barth syndrome population is small and may not generalise to other conditions or populations. SS-31 enhances muscle performance and endurance in preclinical models, but long-term safety outside the approved indication is still under study.
MOTS-c safety:
- A mouse neuropathic pain study reported less tolerance, gastrointestinal inhibition and motor impairment with experimental MOTS-c treatment than with morphine under the tested conditions.[16] This limited comparison does not establish general safety.
- A well-characterised safety profile for administered native MOTS-c has not been established. Endogenous-level studies do not test administration safety, and CB4211 analogue findings cannot fill that gap. Long-term effects, off-target actions and exposure-related risks remain uncertain.
- Specific gaps: The available evidence does not provide an adequate basis to assess reproductive toxicity, carcinogenicity, chronic exposure or interactions with metabolic medicines in humans.
Boundary statement: Remy Research products are labelled “for research use only.” No safety should be inferred for self-administration or clinical use from their provision as reagents. No dosing, route of administration, cycle length, or stacking advice is given. For more on research-grade peptide sourcing, see Peptide Supplier Checklist: What to Record.
Winner: SS-31 for better-characterised safety, not proven superior safety. Elamipretide has a characterised safety profile in defined patients and trials. MOTS-c remains less characterised, with greater unknowns. Neither status should be extrapolated to unsupervised use of research-grade material.
Decisive Factor 4: Practical Use in Laboratory Models
Beyond mechanism and evidence, practical considerations – which assays, which tissues, which readouts – often determine which peptide a lab should procure.
SS-31:
- Particularly suited to studies of mitochondrial respiration, mitochondrial ROS production, cardiolipin composition and redox proteomics. These are potential experimental readouts, not guaranteed responses in every tissue or model.
- Published animal experiments include ATP production capacity, P/O ratio, fatigue resistance and ischemia–reperfusion injury as endpoints. The aged-mouse skeletal-muscle study also measured the glutathione redox ratio, providing a concrete example of a redox readout.[4]
- Typical assays: H₂O₂ emission, cardiolipin mass spectrometry, ETC complex activity, redox proteomics, mitochondrial membrane potential, electron microscopy of cristae.
MOTS-c:
- More often applied in chronic metabolic experiments: diet-induced obesity, insulin resistance, sarcopenic obesity, or aging cohorts, focusing on glucose tolerance, insulin signaling pathways, and inflammatory markers. The MOTS-c peptide is relevant for cell models of stress adaptation, nuclear transcriptional responses, and AMPK pathway modulation.
- Typical assays: glucose uptake assays, lipid accumulation quantification, cytokine profiling, AMPK phosphorylation, PGC-1α expression, exercise performance metrics in animals.
Practical notes for both:
- Both peptides require attention to peptide stability, proper storage conditions, and avoidance of repeated freeze–thaw cycles in lab workflows. Degradation can introduce confounding variables in sensitive assays.
- Consulting Certificates of Analysis (COAs), HPLC purity data, and mass-spec identity confirmation is essential when planning experiments – particularly for studies involving proteins, lipids, or cell-based readouts where impurities could interfere. See How to Read a Peptide COA for a worked example.
Winner: Depends on experimental endpoint. SS-31 is usually the stronger choice for mechanistic mitochondrial bioenergetics – membrane structure, electron transport, oxidative damage, and recovery from acute injury. MOTS-c is better for systemic metabolic phenotypes – glucose metabolism, body composition, exercise biology. Match peptide to primary endpoint rather than trend.
SS-31 vs MOTS-c: Which Should Your Lab Choose?
There is no universal “better” peptide in mitochondrial medicine research – only a better fit for a given hypothesis. The comparison above consistently shows that these compounds operate through distinct mechanisms at different biological levels, with different evidence maturity.
- Choose SS-31 if:
- Your primary outcome is mitochondrial membrane function, cardiolipin biology, ETC efficiency, or muscle/cardiac fatigue resistance.
- You are modelling disease involving mitochondrial dysfunction at the membrane or respiratory chain level (Barth syndrome, ischemia reperfusion injury, aging-related decline in skeletal muscle function).
- You need a model compound with a relatively well-mapped human trial history and a defined regulatory indication for translational context.
- Choose MOTS-c if:
- Your project focuses on insulin resistance, obesity, exercise biology, aging-related metabolic dysfunction, or mitochondrial–nuclear signaling.
- You are exploring emerging mitochondrial-derived peptides and are comfortable working in an earlier-stage evidence landscape with an emphasis on metabolic regulation and stress adaptation.
- Your readouts centre on AMPK activation, glucose utilization, lipid metabolism, or cellular metabolism broadly.
While some online sources speculate about combining SS-31 and MOTS-c, no published controlled combination human trial was identified in the sources reviewed. Synergy claims remain unproven hypotheses. Laboratory interaction studies need appropriate factorial controls.
Remy Research supplies research-grade SS-31 and MOTS-c for in-vitro use only, not for human or veterinary administration. Published animal studies discussed here do not change that product-use boundary.
Our Research Standards
This comparison prioritizes primary literature, trial registries and regulator records, and keeps cell, animal and human evidence apart. Where the human record is empty, we say so directly. No therapeutic, dosing or administration guidance is given. Read our editorial policy →
Frequently Asked Questions About SS-31 vs MOTS-c
These address common research planning questions – not clinical decision-making or self-experimentation.
Can SS-31 and MOTS-c be used together in the same experiment?
Co-exposure can be investigated in vitro with appropriate controls. The sources reviewed do not establish a validated combination protocol from human data. Researchers should design factorial experiments (SS-31 alone, MOTS-c alone, both, and vehicle controls) to test interaction effects rather than assume synergy. No advice is given on co-administration in humans or animals outside controlled research protocols.
Is SS-31 safer or more “proven” than MOTS-c for human use?
Elamipretide has undergone formal clinical testing and achieved US accelerated approval in a specific ultra-rare disease (Barth syndrome), so its safety profile is more characterised than that of MOTS-c. This does not mean SS-31 is “safe” for off-label or unsupervised use – especially not in the form of research-grade reagents. MOTS-c remains investigational with much less human data; unknowns are greater. Remy Research does not make or support any therapeutic safety claims for either peptide.
Are SS-31 or MOTS-c approved for clinical use in the UAE or GCC?
Regulatory approvals are jurisdiction-specific. US FDA decisions do not automatically apply to the UAE, Saudi Arabia or other GCC markets. The verified US approval is Forzinity’s specific accelerated approval for muscle strength in Barth syndrome patients weighing at least 30 kg. This review has not established current UAE or other GCC marketing authorisations for either compound; local status must be checked with the relevant regulator. Trial registration and availability from a research supplier do not establish clinical approval. Remy Research supplies research-use-only reagents.
Where can I find deeper, compound-specific reviews of SS-31 and MOTS-c?
Remy Research’s Peptide Research Library includes detailed posts on both compounds:
- SS-31 Peptide Benefits, Side Effects and FDA Approval – mechanisms, trial overviews, safety signals.
- MOTS-c Benefits and Side Effects: What Studies Show – metabolic mechanisms, aging data, safety gaps.
For the most current data, consult primary literature, clinical trial registries (e.g. ClinicalTrials.gov), and regulatory assessment reports directly.
Sources
- Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171(8):2017-2028. doi: 10.1111/bph.12468 · PMID: 24134698 ↩
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi: 10.1016/j.cmet.2015.02.009 · PMID: 25738459 ↩
- U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. Press announcement, September 19, 2025. fda.gov ↩
- Campbell MD, Duan J, Samuelson AT, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radic Biol Med. 2019;134:268-281. doi: 10.1016/j.freeradbiomed.2018.12.031 · PMID: 30597195 ↩
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8). doi: 10.1681/ASN.2012121216 · PMID: 23813215 ↩
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524.e7. doi: 10.1016/j.cmet.2018.06.008 · PMID: 29983246 ↩
- von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3). doi: 10.1152/japplphysiol.00706.2019 · PMID: 34351816 ↩
- ClinicalTrials.gov. NCT03998514, Phase 1a/1b study of CB4211 in healthy non-obese subjects and subjects with NAFLD (completed; 88 enrolled; record checked November 14, 2026). clinicaltrials.gov/study/NCT03998514 ↩
- Gudiksen A, Hansen CC, van der Stede T, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radic Biol Med. 2026;246:682-696. doi: 10.1016/j.freeradbiomed.2026.01.002 ↩
- U.S. Food and Drug Administration. Drug Trials Snapshots: Forzinity (SPIBA-201; approval date September 19, 2025). fda.gov ↩
- Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3). doi: 10.1212/WNL.0000000000207402 · PMID: 37268435 ↩
- Yu WD, Kim YJ, Cho MJ, et al. The mitochondrial-derived peptide MOTS-c promotes homeostasis in aged human placenta-derived mesenchymal stem cells in vitro. Mitochondrion. 2021;58:135-146. doi: 10.1016/j.mito.2021.02.010 ↩
- Ramanjaneya M, Jerobin J, Bettahi I, et al. Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects. Clin Endocrinol (Oxf). 2019;91(2). doi: 10.1111/cen.14007 · PMID: 31066084 ↩
- CohBar, Inc. Press release dated November 5, 2018 (Form 8-K, Exhibit 99.1): CB4211 described as an analog of MOTS-c. sec.gov ↩
- Stealth BioTherapeutics Inc. FORZINITY (elamipretide) injection, prescribing information, 2025. accessdata.fda.gov ↩
- Jiang J, Xu L, Yang L, Liu S, Wang Z. Mitochondrial-derived peptide MOTS-c ameliorates spared nerve injury-induced neuropathic pain in mice by inhibiting microglia activation and neuronal oxidative damage in the spinal cord via the AMPK pathway. ACS Chem Neurosci. 2023;14(12). doi: 10.1021/acschemneuro.3c00140 · PMID: 37285113 ↩
For catalog details, see the SS-31 40mg pen and the MOTS-c 10mg research vial. For editorial standards, continue to the editorial policy.